Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Merck earnings top estimates amid solid demand for Keytruda cancer drug Uber gross bookings growth slows, shares slide Comcast tops revenue expectations on Olympics ad boost, blockbuster releases ...

Merck (NYSE:MRK) is scheduled to announce Q3 earnings results on Thursday, October 31st, before market open. Analysts anticipate a profit of $1.57 per share (-26.3% Y/Y) on revenue of $16.51B (+3.2% Y ...

Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer, opening up another front in its ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best medical stocks to ...

A new and viral political video featuring men declaring they are "man enough" to support Vice President Kamala Harris’ presidential campaign is stacked with Hollywood actors and comedians.

in combination with Keytruda, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with resectable Stage II, IIIA or IIIB non-small cell lung cancer who did not achieve a pathological ...

The stock market has been pushing up Summit's stock price because there's a chance that ivonescimab could unseat Merck's Keytruda as ... the pre-commercial company boasts a $14.6 billion market ...

"Must-see Kamala ad," Claremont Institute fellow David Reaboi quipped. "Not only do they have no idea how actual men speak, they couldn’t find any convincing male actors." The original YouTube ...